cb-839
Other B-cell NHL Subtypes, Including WM
Calithera Biosciences, IncPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Other B-cell NHL Subtypes, Including WM cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pomalidomide University of Michigan Rogel Cancer Center | Phase 1 | CC |
Telaglenastat Calithera Biosciences, Inc | Phase 1 | CC |
Same molecule, other indications
cb-839 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →